Tumor-Derived Peptides Trigger Strong Anti-Cancer Immune Responses in Mice

What the researchers found

Two nonameric peptides (Peptide32-40 and Peptide175-183) identified from canine MMP-7 via immunoinformatics induced significant lymphocyte proliferation and IFN-γ production from CD8+ T cells in BALB/c mice immunized with a cMMP-7 DNA vaccine.

The DNA vaccine itself triggered strong CD8+ cytotoxic T lymphocyte (CTL) and Th1-type responses with high IFN-γ levels. The cross-species (xenovaccine) approach — using canine MMP-7 in mice — successfully overcame the immunological tolerance that typically limits vaccines targeting endogenous tumor-associated antigens.

Why it matters

MMP-7 is overexpressed in many human cancers and promotes tumor invasion and metastasis. Developing a vaccine that trains the immune system to attack MMP-7-expressing tumor cells could provide a new weapon against cancer spread. The xenovaccine strategy — using a slightly different species' version of the protein — is an innovative way to overcome the immune system's reluctance to attack its own proteins.

How the study worked

Immunoinformatics was used to predict MHC class-I binding peptides from canine MMP-7 protein sequence. A cMMP-7 DNA vaccine was constructed and administered to BALB/c mice. Immune responses were measured by assessing CD8+ T cell activation, lymphocyte proliferation, IFN-γ production, and antibody responses. The two predicted peptides were tested individually for their ability to stimulate T cells from vaccinated mice.

What this study cannot tell us

This is a mouse study using a xenogeneic (cross-species) approach — results may not directly predict human immune responses. No tumor challenge experiments were described to confirm whether the immune response actually prevents or slows tumor growth. The MHC binding predictions were computational and the peptides were tested only in the context of prior DNA vaccination, not as standalone peptide vaccines.

How to read the evidence

This is a preclinical animal study using a mouse model. While the immune responses are clearly demonstrated, no tumor protection data or clinical validation is available.

When this study was published

Published in 2021, this study is relatively recent and contributes to the active field of peptide-based cancer vaccine development.

The bigger picture

Peptide-based cancer vaccines are a growing field within immunotherapy. While checkpoint inhibitors and CAR-T cells have dominated recent oncology advances, peptide vaccines offer a potentially simpler, more affordable, and safer approach. This study contributes to the evidence that computationally identified peptides can elicit meaningful anti-tumor immune responses, and the xenovaccine concept could be broadly applicable to other tumor-associated antigens.

Questions still open

• Do these MMP-7-derived peptides protect against tumor growth in mouse tumor challenge models?
• Can equivalent human MMP-7-derived peptides elicit similar immune responses for human cancer vaccination?
• Would a multi-epitope vaccine combining these peptides with others provide broader and more durable anti-tumor immunity?

Common questions

Read the original research

MMP-7 derived peptides with MHC class-I binding motifs from canine mammary tumor tissue elicit strong antigen-specific T-cell responses in BALB/c mice.

Molecular and cellular biochemistry, 476(1), 311-320

Citation

Yadav, Pavan Kumar; Gupta, Shishir Kumar; Kumar, Saroj; Ghosh, Mayukh; Yadav, Brijesh Singh; Kumar, Dinesh; Kumar, Ajay; Saini, Mohini; Kataria, Meena. (2021). MMP-7 derived peptides with MHC class-I binding motifs from canine mammary tumor tissue elicit strong antigen-specific T-cell responses in BALB/c mice.. Molecular and cellular biochemistry, 476(1), 311-320. https://doi.org/10.1007/s11010-020-03908-2